Diplomat Pharmacy Inc (NYSE:DPLO) shares fell 0% during trading on Tuesday . The stock traded as low as $20.27 and last traded at $21.90. 2,430,000 shares changed hands during trading, an increase of 171% from the average session volume of 896,144 shares. The stock had previously closed at $21.90.
Several brokerages have commented on DPLO. Deutsche Bank downgraded Diplomat Pharmacy from a “buy” rating to a “hold” rating and lifted their target price for the stock from $22.00 to $29.00 in a report on Friday, February 2nd. Robert W. Baird lowered Diplomat Pharmacy from an “outperform” rating to a “neutral” rating and lowered their price objective for the stock from $24.00 to $18.00 in a research report on Thursday, November 16th. Lake Street Capital started coverage on Diplomat Pharmacy in a research report on Friday, February 9th. They issued a “buy” rating and a $35.00 price objective for the company. Credit Suisse Group raised Diplomat Pharmacy from an “underperform” rating to a “neutral” rating and set a $28.00 price objective for the company in a research report on Thursday, January 25th. Finally, Needham & Company LLC lifted their price objective on Diplomat Pharmacy from $23.75 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, November 8th. Nine investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $24.79.
The company has a quick ratio of 0.82, a current ratio of 0.97 and a debt-to-equity ratio of 0.70. The firm has a market cap of $1,617.78, a PE ratio of 99.24 and a beta of 1.06.
Institutional investors have recently modified their holdings of the stock. New York State Common Retirement Fund increased its holdings in Diplomat Pharmacy by 11.4% during the 2nd quarter. New York State Common Retirement Fund now owns 52,900 shares of the company’s stock worth $783,000 after purchasing an additional 5,399 shares in the last quarter. Vanguard Group Inc. increased its holdings in Diplomat Pharmacy by 5.4% during the 2nd quarter. Vanguard Group Inc. now owns 4,077,145 shares of the company’s stock worth $60,342,000 after purchasing an additional 210,334 shares in the last quarter. Parametric Portfolio Associates LLC increased its holdings in Diplomat Pharmacy by 54.8% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 86,544 shares of the company’s stock worth $1,281,000 after purchasing an additional 30,645 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Diplomat Pharmacy by 18.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 358,257 shares of the company’s stock worth $5,302,000 after purchasing an additional 54,661 shares in the last quarter. Finally, Voya Investment Management LLC increased its holdings in Diplomat Pharmacy by 10.4% during the 2nd quarter. Voya Investment Management LLC now owns 21,641 shares of the company’s stock worth $320,000 after purchasing an additional 2,040 shares in the last quarter. 73.44% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3230370/diplomat-pharmacy-dplo-stock-price-down-0.html.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.